advertisement
Abstract #47749 Published in IGR 13-4
Gene therapy for retinal ganglion cell neuroprotection in glaucoma
Wilson AM; Di Polo AGene Therapy 2011;
Glaucoma is the leading cause of irreversible blindness worldwide. The primary cause of glaucoma is not known, but several risk factors have been identified, including elevated intraocular pressure and age. Loss of vision in glaucoma is caused by the death of retinal ganglion cells (RGCs), the neurons that convey visual information from the retina to the brain. Therapeutic strategies aimed at delaying or halting RGC loss, known as neuroprotection, would be valuable to save vision in glaucoma. In this review, we discuss the significant progress that has been made in the use of gene therapy to understand mechanisms underlying RGC degeneration and to promote the survival of these neurons in experimental models of optic nerve injury.Gene Therapy advance online publication, 6 October 2011; doi:10.1038/gt.2011.142.
1] Department of Pathology and Cell Biology, Universite de Montreal, Montreal, Quebec, Canada
Classification:
11.9 Gene therapy (Part of: 11 Medical treatment)
11.8 Neuroprotection (Part of: 11 Medical treatment)
3.4.2 Gene studies (Part of: 3 Laboratory methods > 3.4 Molecular genetics)
